Participated · Series B · Mar 2026

Ambrosia Biosciences develops orally bioavailable small molecules targeting metabolic G-protein coupled receptors, including GLP-1, GIP and amylin. The company combines structural biology with advanced computational chemistry to design molecules with differentiated pharmacology intended for both standalone therapies and strategic combinations. Its lead program is an oral small molecule GLP-1 candidate that the company intends to advance into a Phase 1 clinical trial. The recent $100 million Series B committed capital is intended to fund Ambrosia through clinical trial initiation and to support continued development of its broader small-molecule pipeline. The company is based in Boulder, Colorado, and announced a board appointment tied to the financing.

Participated · Seed · Feb 2026

Comeryx is an AI-native, digital MGA that uses advanced automation and data-driven underwriting to serve the excess & surplus (E&S) insurance needs of small-business artisan contractors. Its platform streamlines quoting, binding, and servicing, aiming to lower acquisition costs and improve loss ratios relative to traditional carriers. The company targets an addressable market of more than 500,000 U.S. artisan contracting firms with under $10 million in annual revenue, positioning itself as a focused specialist in an underserved niche. Headquartered in Denver, Colorado, Comeryx is led by CEO Dax Craig (formerly Pie Insurance and Valen Analytics) alongside seasoned insurtech, engineering, analytics, and underwriting executives. The business plans to invest heavily in AI model refinement, geographic expansion, and product breadth as it scales. Although no premium-written or revenue figures were disclosed, the recent seed financing provides the runway needed to grow its book and validate underwriting performance. Future priorities include building distribution partnerships and extending coverage classes to capture a larger share of the small-business E&S market.

Participated · Series A · Feb 2026

RapidFort delivers a modern software supply chain security platform built for the AI era. The solution embeds continuous vulnerability analysis, automated remediation, hardening, and protection directly into CI/CD workflows so issues are fixed as code ships. Its catalog of hardened, near-zero-CVE container images across major Linux distributions and runtime intelligence can shrink attack surfaces by up to 90 percent without requiring code changes. The platform is built for regulated environments, supporting FedRAMP, CMMC, ATO, CRA, and NIS2 compliance with auditable security controls. Management reports "accelerating revenue momentum" as organizations shift from reactive scanning to continuous elimination of risk, though no specific revenue figures were disclosed. Proceeds from the Series A will fund go-to-market expansion, deeper enterprise integrations, and further product innovation around automated remediation and continuous attack surface reduction.

Participated · Series A · Nov 2023

ClinOne offers a single platform that connects, informs, and empowers patients, care partners, and trial sites, supporting trial awareness, consent management, and patient experience/retention. The platform is underpinned by comprehensive data-insights tools and standards-based interoperability to simplify processes. Its solutions are used by more than 80 sponsors, CROs, and site networks across 60 countries and serve therapeutic areas including Oncology, Rare Disease, Pediatrics, the Elderly, and CNS. ClinOne states its solutions are proven to reduce risk and simplify processes for sponsors and sites. The company intends to use newly raised funds to expand operations and its business reach. ClinOne is based in Needham, MA. ClinOne offers a platform for trial and consent management, patient engagement, comprehensive data-insights tools, and interoperability to connect patients, caregivers, and sites in clinical trials. The platform is used by more than 80 sponsors, CROs, and site networks across 60 countries. Its product aims to reduce risk and simplify complex processes across therapeutic areas including oncology, rare disease, pediatrics, the elderly, and CNS. Led by CEO Andrea Valente, ClinOne emphasizes patient and site empowerment through its suite of tools. The company recently completed a $3M Series A to support growth. It intends to use the funds to accelerate platform development and broaden its customer reach. ClinOne operates the ClinOne and ClinTrialConnect platforms to enable pharmaceutical sponsors, research sites and participants to perform and automate recruitment, study execution, compliance and patient retention from any location worldwide. Its modular product suite includes patient recruitment, remote consent (eConsent), patient-reported outcomes and surveys (ePRO), dosing management and remote vital-sign data collection, and it integrates with home healthcare visits and telemedicine video visits. ClinOne conducts clinical trials in 55 countries across 43 languages. The company added the CU Healthcare Innovation Fund as lead investor in a Series-A financing with a first closing of $3.6 million. Management said the funding will be used to expand the product suite and sales efforts to meet high demand. The announcement also referenced a partnership with portfolio company BioIntelliSense to enable more robust remote patient monitoring in clinical trial management.

Participated · Series B · Jun 2022

Mineralys Therapeutics operates in the biotechnology sector, concentrating on the development of therapeutic innovations. The company recently drew attention amid a broader surge in biotech valuations. According to the article, Mineralys secured $9.5 million in new capital from Findell Capital Management, giving it additional liquidity to advance its research initiatives. While the report does not outline specific drug candidates or clinical programs, the fresh funding underscores investor confidence in the firm’s scientific direction. The financing also signals the company’s intent to accelerate upcoming milestones and strengthen its operational footing. No revenue figures, user metrics, or detailed pipeline information were disclosed in the article.